Cargando…
Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
Insulin resistance is a major contributor to the pathogenesis of several human diseases, including type 2 diabetes, hypertension, and hyperlipidemia. Notably, insulin resistance and hypertension share common abnormalities, including increased oxidative stress, inflammation, and organelle dysfunction...
Autores principales: | Lee, Jin Wook, Gu, Hyun-Oh, Jung, Yunshin, Jung, YunJae, Seo, Seung-Yong, Hong, Jeong-Hee, Hong, In-Sun, Lee, Dae Ho, Kim, Ok-Hee, Oh, Byung-Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238434/ https://www.ncbi.nlm.nih.gov/pubmed/37121975 http://dx.doi.org/10.1038/s12276-023-00982-6 |
Ejemplares similares
-
Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011) -
Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
por: Choisy, Stéphanie C., et al.
Publicado: (2015) -
Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis
por: Lee, Seul-Gee, et al.
Publicado: (2019) -
No effect of the angiotensin receptor blocker candesartan on
cerebrovascular autoregulation in rats during very high and low sodium
intake
por: Sigurdsson, Sigurdur T, et al.
Publicado: (2019) -
Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis
por: Hwang, Byungtae, et al.
Publicado: (2023)